Introduction {#sec1-1}
============

*Campylobacter* spp. can cause gastrointestinal and extra-intestinal infections \[[@ref1]\]. Although the majority of cases (≥90%) of intestinal campylobacteriosis are caused by *Campylobacter jejuni* and *Campylobacter coli*, a small number of these cases are also caused by *Campylobacter fetus* \[[@ref2]\]. Among these, *C. fetus* is the most common cause of *Campylobacter* bacteremia. The frequency of detection in blood cultures varies between 19% and 53% \[[@ref6]\] of all campylobacterioses. The reported case fatality rate of invasive *C. fetus* infections is at 14% \[[@ref9]\]. Due to the high incidence rate of campylobacteriosis worldwide, this shows that *C. fetus* infections occur frequently and have the potential to become a significant public health issue. However, relatively little is known about the infection sources and the people at risk, so far. Most reported *C. fetus* infections were observed in AIDS patients and other immunocompromised individuals \[[@ref1], [@ref10]\].

*C. fetus* is a Gram-negative, microaerophilic bacterium, growing between 25 °C and 37 °C. Clinical symptoms of human *C. fetus* infection vary from acute diarrhea to systemic illness \[[@ref11], [@ref12]\], and the presentation of these symptoms depends on localization of the disseminated pathogen. Septicemia with fever, but without apparent localized infection, for example, is reported in 24% to 41% of cases \[[@ref7], [@ref9]\]. Other manifestations can be the result of neurological infections (i.e., meningoencephalitis, meningitis, or brain abscesses), arthritis, lung abscesses, osteomyelitis, and perinatal infections (i.e., abortion, infection in utero, or placentitis) \[[@ref12]\]. Furthermore, *C. fetus* infections may also cause vascular pathology (i.e., endocarditis, pericarditis, vasculitis, and mycotic aneurysms) \[[@ref13]\].

Currently, 3 subspecies of *C. fetus* are known. These are *C. fetus* subspecies *fetus (Cff), C. fetus* subspecies *venerealis (Cfv)*, and *C. fetus* subspecies *testudinum (Cft).* For *Cfv*, also the biovar intermedius *(Cfvi)* has been identified in previous studies \[[@ref14], [@ref15]\]. Subspecies *Cff* and *Cfv* are primarily associated with mammals \[[@ref13], [@ref14]\], whereas the third subspecies *Cft* is associated with reptiles \[[@ref15], [@ref16]\]. *Cff* and *Cfv* are genetically very closely related \[[@ref17], [@ref18]\] but differ in host adaption. *Cff* can cause sporadic infections in humans and abortion in sheep and cattle and can be isolated from different sites in different hosts \[[@ref19]\]. Occurrence of *Cfv* is restricted to the genital tract of cattle and is furthermore responsible for bovine genital campylobacteriosis (BGC). This syndrome is characterized by fertility problems in cattle \[[@ref20]\]. Previous studies have demonstrated a substantial genetic divergence between strains of reptile and mammal origins \[[@ref21], [@ref22]\], and molecular and phenotypic characterization of human cases and 3 reptiles identified a new subspecies and proposed the name *C. fetus* subsp. *testudinum* subsp. nov. \[[@ref15], [@ref23]\].

In recent years, intact cell matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (ICMS) became a standard method for microbial species identification in clinical diagnostic laboratories \[[@ref24], [@ref25]\]. MALDI-TOF mass spectrometry (MS) also offers the opportunity to classify unknown bacterial isolates by identifying similarities in mass spectra of unknown bacteria and biomarkers in existing databases, a procedure referred to as phyloproteomics \[[@ref26]\]. Typing methods, which are based on mass spectrometric analysis, are generally known as proteotyping \[[@ref27]\] and have previously been used for characterization of microbial communities, tissues, individual proteins, viruses, and bacteria for several years now \[[@ref28]\]. Among clinically relevant bacteria *Salmonella* serotypes, *Clostridioides difficile* polymerase chain reaction (PCR) ribotypes and methicillin-resistant *Staphylococcus aureus* lineages have been shown to be detectable by proteotyping, to name just a few \[[@ref32]\].

Previous studies of our working group demonstrated the potential of bacterial subtyping on *Campylobacter* species in the clinical context, as it was possible to differentiate clinically relevant from clinically less relevant subgroups ([Figure 1](#fig001){ref-type="fig"}) \[[@ref35]\]. At the heart of our approach is a list of allelic isoforms that resulted from non-synonymous mutations and posttranslational modifications in biomarker gene sequences, which are detectable as mass shifts in MALDI-TOF spectra. In this way, a combination of amino-acid sequences specific for each of the isolates to be typed can be derived, in a similar manner as for multilocus sequence typing (MLST). By using proteotyping, only the changes in mass associated with a certain set of allelic isoforms of the same protein are taken into account for the derivation of phylogeny, whereas the visibility or absence of particular masses, as well as their intensity, is not considered. This improves the measurement accuracy, wherefore ICMS is a very promising subtyping approach and a realistic alternative to currently used sequence-based techniques \[[@ref37]\].

The goal of this study was to complete the set of typing schemes for clinically relevant *Campylobacter* species by developing a *C. fetus*-specific proteotyping scheme. A set of 41 *C. fetus* isolates covering all currently known subspecies of *C. fetus* was used. All isolates were characterized by proteotyping and MLST, followed by the deduction of the phylogenetic relations.

Materials and Methods {#sec1-2}
=====================

C. *fetus* Isolates {#sec2-1}
-------------------

The test cohort was compiled in way that all subspecies of the bacterial species were represented. In total, 41 *C. fetus* isolates were included in our study: 20 *Cff*, 11 *Cfv*, 7 *Cft*, and 3 *Cfvi* isolates ([Table 1](#table001){ref-type="table"}). The isolates were of different biological origins, namely, preputial washing of cattle (4 *Cff*, 7 *Cfv)*, vaginal mucus of cattle (2 *Cfv)*, fetuses of cattle (2 *Cfv)*, cattle (not further specified, 3 *Cfv)*, bovine sperm (1 *Cff)*, bull genitals (1 *Cff)*, calf fetus (2 *Cff)*, intestinal content of a calf (1 *Cff)*, intestinal content of a pig (1 *Cff)*, fetus brain of a sheep (1*Cff)*, reptile cloak swab (3 *Cft)*, human blood culture (7 *Cff*, 4 *Cft)*, and 2 *Cff* strains of unknown origin. Animal isolates were provided by the Friedrich-Loeffler-Institut Bundesforschungsinstitut für Tiergesundheit, Jena, Germany. The following strains were received from the Belgian coordinated collections of microorganisms (BCCM; <http://bccm.belspo.be/about-us/bccm-lmg>): LMG6443 *(Cfv)*, LMG6442 *(Cff)*, LMG6570 *(Cfv)*, LMG27499 *(Cft)*, LMG06569 *(Cff)*, LMG06571 *(Cff)*, and LMG06727 *(Cff).* Human blood culture isolates were provided by the routine diagnostic laboratory of the University Medical Center, Göttingen, Germany ([Table 1](#table001){ref-type="table"}).

Bacterial Culture Conditions {#sec2-2}
----------------------------

*C. fetus* isolates used in the experiments were kept as cryobank stocks (Mast Diagnostica, Reinfeld, Germany) at --80 °C. For the subsequent MALDITOF MS analysis, the isolates were incubated under microaerophilic conditions (5% O2, 10% CO2, and 85% N2) in Mueller--Hinton agar supplemented with horse blood at 37 °C for 2--3 days.

Preparation of Matrix Solution {#sec2-3}
------------------------------

As part of the measurement preparation α-cyano-4-hydroxy-cinnamic acid (HCCA) purified matrix substance (Bruker Daltonics, Bremen, Germany) was dissolved in standard solvent (acetonitrile 50%, trifluoroacetic acid 2.5% in ddH~2~O) to 10 mg HCCA/mL. Purified recombinant human insulin (Sigma-Aldrich, Taufkirchen, Germany) was added to the HCCA solution as an internal calibrant to a final concentration of 10 pg/μL. The exact mass of the internal calibrant was experimentally determined (m/z = 5806.1) with reference to the Bruker Test Standard (BTS). The calibrant did not overlap with any of the biomarker masses of interest and allowed a very precise internal mass calibration of the spectra.

MALDI-TOF Mass Spectrometry {#sec2-4}
---------------------------

To prepare samples for the measurements, 2 different variants were used: smear preparation and formic acid/acetonitrile extraction. Smear preparation by experience yields clearer peaks in the *m/z* range \<10,000 Da, whereas the extraction variant allows more precise analysis in the field \>10,000 Da \[[@ref39]\].

The samples for the measurements were prepared as described before \[[@ref37], [@ref39]\]. In the measurement process, 600 spectra (mass range 2 to 20 kDa) were obtained in 100-shot steps on an Autoflex III system and summed up. If the MALDI Biotyper (Database release 2016) identification score values were ≥2.00, they were considered correct.

Identification of Biomarkers in ICMS Spectra {#sec2-5}
--------------------------------------------

The obtained mass spectra were analyzed by standard algorithms of FlexAnalysis (Bruker Daltonics, Bremen, Germany). Initially, spectra were internally calibrated to the spiked human insulin peak. Subsequently, the baseline was subtracted, and the spectra were smoothened (standard MBT method).

For determination of the theoretical average weight of the amino acid sequences corresponding to the respective open reading frames of ribosomal proteins, the amino acid sequences were uploaded one by one to the ExPASy Bioinformatics Resource Portal (https://web.expasy.org/compute_pi/), where a molecular weight calculator tool is provided.

Proteins used for previous proteotyping schemes sometimes underwent posttranslational modifications \[[@ref40], [@ref41]\]; therefore, further molecular weights were calculated for each biomarker, taking into account potential proteolytic removal of the *N*-terminal methionine (--131.04 Da), acetylation, phosphorylation, formylation, and methylation ([Table 2](#table002){ref-type="table"}).

Biomarker masses observed in the reference genome of reference strain LMG 6442 (NCTC 10842) ([Figure 2](#fig002){ref-type="fig"}) were matched to the calculated masses. In contrast, biomarker masses are observed in the spectrum of clinical isolates, which could not be assigned to the calculated masses from the *C. fetus* reference genome, and the spectra were considered as novel isoforms of the particular biomarker.

For each isolate of the *C. fetus* test cohort, all biomarker genes were amplified by PCR using primers listed in [Table 3](#table003){ref-type="table"}, and the amplicon was sequenced (Microsynth Seqlab, Göttingen, Germany). To confirm the respective allelic isoforms, the gene sequences obtained from the amplicons were translated in silico, and the amino acid sequences were subsequently aligned.

Multilocus Sequence Typing (MLST) {#sec2-6}
---------------------------------

For MLST, a procedure modified from the original typing schemes was used \[[@ref18], [@ref23]\]. In brief, the annealing temperature of the PCR was decreased from 48 °C to 47 °C, and the *glyA2* oligonucleotide primer for the amplification of the *glyA* locus was replaced with the primer *glyS4* \[[@ref18]\]. After concatenating of the MLST gene sequences for each strain, the software MEGA X was also used to construct an MLST-based UPGMA dendrogram \[[@ref42]\].

Phylogenetic and Phyloproteomic Analyses {#sec2-7}
----------------------------------------

An amino acid sequence list of all allelic isoforms of the 9 identified biomarkers was compiled ([Table 4](#table004){ref-type="table"}). GenBank accession numbers for the biomarker sequences observed in this study are listed in [Table 5](#table005){ref-type="table"}.

To analyze the biomarkers\' protein sequences translated from the National Center for Biotechnology Information (NCBI) nucleotide database (Geneious V10.1.3) they were concatenated for each strain and an unweighted pair group method with arithmetic mean (UPGMA) dendrogram (MEGA X) was constructed \[[@ref42]\].

Ethical Approval {#sec2-8}
----------------

Ethical approval for the study was obtained from Ethics Commission of the University Medical Center Göttingen, Germany. No humans, animals, or personalized data were used for this study.

Results and Discussion {#sec1-3}
======================

In 2015, our working group set up a new proteotyping workflow for the proteotyping of microorganisms ([Figure 1](#fig001){ref-type="fig"}) \[[@ref37]\]. Now, the established procedure was used to develop a *C. fetus*-specific proteotyping scheme. According to the standard workflow, masses emerging in the mass spectrum of the genome sequenced *Cff* reference strain LMG 6442 (NCTC 10842) were analyzed, and MS biomarker ions were related with gene products consistent with the observed mass. By evaluating the 67 *C. fetus* nucleotide sequences available in the NCBI database, a collection of allelic isoforms for all biomarkers observed in the reference spectrum was set up ([Table 4](#table004){ref-type="table"}). In accordance with the established proteotyping procedure, mass spectra of all strains included in the test cohort were recorded. Subsequently, spectra were edited (baseline subtraction and smoothing) and overlaid with the spectrum of *Cff* reference strain LMG 6442 (NCTC 10842). Recorded biomarker masses were matched with the calculated average protein masses, and mass shifts in relation to the masses of the references strain were analyzed. After concatenation of amino acid sequences of the biomarkers included in the *C. fetus* typing scheme, a UPGMA tree based on these strain-specific proteotyping-based types was calculated.

Identification of Biomarker Ions {#sec2-9}
--------------------------------

In total, the analysis based on the genome of *Cff* reference strain LMG 6442 (NCTC 10842) yielded nine, single charged biomarker masses between *m/z =* 4300 and 10,300, which were presumptively correlated with a specific gene product. To provide reliable statements on reproducibility of our measurements, the standard deviation was calculated on the basis of 6 measurements. The highest standard deviation (0.959) was observed for isoform 1 of biomarker S20-M, whereas the lowest standard deviation (0.271) was observed for isoform 5 of biomarker L33-M ([Table 6](#table006){ref-type="table"}). The following biomarkers were identified: L36 (4331.35 Da), L34 (4217.26 Da), L32-M (5530.47 Da), L33-M (6205.31 Da), S14-M (6728.11 Da), L29 (6893.22 Da), L24-M (8026.59 Da), S20-M (9741.33 Da), and S19-M (10,277.10 Da). De-methionation was observed for biomarkers L32-M, L33-M, S14-M, L24-M, S19-M, and S20-M ([Table 2](#table002){ref-type="table"}, [Figures 2](#fig002){ref-type="fig"} & [3](#fig003){ref-type="fig"}). In the case of MLST, the established markers are distributed over the whole genome of the reference strain. As the biomarkers identified in this study show a comparable distribution, they were suitable for the deduction of phylogenetic relations.

Comparing *C. fetus* proteotyping biomarkers to biomarkers identified within the context of *C. jejuni* subsp. *jejuni, C. jejuni* subsp. *doylei*, and *C. coli* proteotyping \[[@ref37]\], several differences can be noted: In the case of *C. jejuni* subsp. *jejuni*, 19 biomarkers were identified and associated with the respective peak in the ICMS spectrum, whereas less than half (9) were found for *C. fetus.* Furthermore, biomarker L33 lacked *N*-terminal methionine in the case of *C. fetus* (L33-M) but it was present in *C. jejuni* subsp. *jejuni, C. jejuni* subsp. *doylei*, and *C. coli.* These observations confirm the results published by Fagerquist et al., in which posttranslational modification patterns are microbial species-specific. Within the isolate collection, biomarker mass shifts were observed in 7 out of 9 biomarkers \[[@ref43]\].

Establishment of an Allelic Isoform Database {#sec2-10}
--------------------------------------------

Following the identification of biomarker ions, an amino acid sequence isoform list for each of the biomarkers identified in the previous step was compiled. In this context, we analyzed the 67 *C. fetus* genome sequences that can be found on NCBI. The number of identified isoforms for the respective biomarker varied. The highest number was 6, whereas 1 biomarker showed just a single isoform. Differences were also observed regarding frequency of occurrence; whereas some isoforms occurred in \>99% of the cases, other isoforms were only found once. Regarding single occurrence of isoforms, a sequencing error is possible. Except for biomarker L36, all identified biomarkers showed at least 3 different isoforms, demonstrating their suitability in the *C. fetus* subtyping context.

The amino acid sequences of all biomarker isoform are listed in [Table 4](#table004){ref-type="table"}. Variations of the amino acid sequences obtained by alignment of the sequences are indicated in red; additionally, the computed average protein mass for each isoform is listed. It should be noted that due to some draft genomes in GenBank, the number of available sequences may vary, as there were no contigs with the sequences coding for each biomarker in all genomes.

MLST and Proteotyping of the Isolate Collection {#sec2-11}
-----------------------------------------------

To proof functionality of the *C. fetus* proteotyping scheme the test cohort (41 *C. fetus* strains) was typed by MLST, as well as proteotyping. The composition of the test cohort was such that all known subspecies of the species were covered. The isolate collection comprised the following 14 MLST sequence types: ST2 (3 isolates), ST3 (7 isolates), ST4 (14 isolates), ST5 (2 isolates), ST6 (4 isolates), ST11 (1 isolate), ST15 (2 isolates), ST16 (1 isolate), ST20 (2 isolates), ST27 (1 isolate), ST30 (1 isolate), ST31 (1 isolate), ST66 (1 isolate), and ST68 (1 isolate, [Table 1](#table001){ref-type="table"}).

The concatenated amino acid sequences of the different biomarkers yielded four proteotyping-derived types ([Figure 4](#fig004){ref-type="fig"}, right dendrogram). Proteotyping-derived type A comprised most of the *Cff* and *Cfv* isolates (31/41). More precisely, it comprised 3 MLST-ST2 isolates, 7 MLST-ST3 isolates, 14 MLST-ST4 isolates, 4 MLST-ST6 isolates, 1 MLST-ST11 isolate, and 1 MLST-ST68 isolate.

Proteotyping-derived type B consisted of two *Cff* MLST-ST 20 isolates, while proteotyping-derived type C consisted of one MLST-ST5 isolate *(Cff).*

The most interesting findings were that proteotyping-derived type D consisted only of *Cft* isolates. Regarding MLST sequence types, it comprised particularly 1 isolate of ST16, 2 isolates of ST15, 1 isolate of ST27, 1 isolate of ST30, 1 isolate of sequence type 31, and 1 isolate of ST61.

Identification of Allelic Isoforms {#sec2-12}
----------------------------------

The test cohort was measured in exactly the same manner as it was done for the reference strain LMG 6442 (NCTC 10842). The evaluation of the measurements of mass spectra of the strains was done based on the comparison with the spectrum of this reference strain. Observed mass shifts were compared to the sequence list of amino acid isoforms, whereby a particular allelic isoform could be identified.

If two different isoforms with the same mutation at different positions were observed, which though did not differ regarding mass difference to the reference isoform, the variants were further examined by DNA sequencing. In the test cohort, 3 allelic isoforms for biomarker L33-M (RpmG) and 2 for biomarkers L34 (RpmH), L32-M (RpmF), L29 (RpmC), L24-M (RplX), S20-M (RpsT), and S19-M (RpsS) were detected. For biomarkers L36 (RpmJ) and S14-M (RpsN), only one allelic isoform was identified ([Table 2](#table002){ref-type="table"}, [Figure 3](#fig003){ref-type="fig"}).

Construction of an UPGMA-Dendrogram {#sec2-13}
-----------------------------------

To deduce the phylogenetic relationships of the species, amino acid sequences of the 9 identified proteotyping biomarkers were fused into a single sequence. The concatenated sequence was then further processed with the MEGA X software to calculate a phyloproteomic tree (UPGMA). The 9 identified biomarkers allowed a clear differentiation of a group of *Cff* and *Cfv* strains from a group of utterly *Cft* strains. In order to assess the quality of the proteotyping results, another UPGMA tree was calculated based on MLST data ([Figure 4](#fig004){ref-type="fig"}). Comparative analysis of the trees revealed some differences between the two resulting phylogenies. While the test cohort was differentiated into 14 MLST sequence types, the proteotyping-based analysis led to a division into only 4 different groups. The most interesting finding was that proteotyping-based type D comprised all of the *Cft* isolates, showing that our approach here is comparable to the quality of the current gold standard MLST.

Unfortunately, the MLST-ST4 corresponding to the subspecies *Cfv* could not be differentiated by means of proteotyping. Here, proteotyping proves to be inferior to MLST in its discriminatory resolution.

A previous study by Fitzgerald et al. showed that it is possible to distinguish *Cft* from other *C. fetus* subspecies. Based on multiple unidentified biomarker peaks, a dendrogram was calculated using Pearson correlation \[[@ref15]\]. A factor, which reduces the informative value of these results, was the lack of knowledge about the proteins responsible for each of the discriminating peaks.

In contrast to this study, we were able to identify at least 9 defined ribosomal proteins as biomarkers. As *Cft* strains exhibited different biomarker isoforms compared to the other two *C. fetus* subspecies, they could be clearly differentiated. PCR and subsequent Sanger sequencing of the respective biomarkers further confirmed these differences.

Regarding the limitations of proteotyping, the number of sequence data available is decisive for the quality of the typing scheme. In the case of *C. fetus*, much less sequences (67) were available as compared to *C. jejuni* subsp. *jejuni* (more than 3000) \[[@ref37]\]. Another factor affecting the quality of the typing scheme is the number of biomarkers it comprises. Further studies should therefore focus on the identification of additional reliable biomarkers that can be included in the existing scheme.

The prerequisite for the application of the technique is the visibility of all biomarkers of the typing scheme. If this is not the case, it is advisable to use sequence-based techniques.

Conclusion {#sec1-4}
==========

As the results obtained so far demonstrate, proteotyping is a promising tool for microbial typing at the species, subspecies, and even below subspecies levels. A smart bioinformatics solution and the development of an easy-to-handle user interface would allow the application of the technique in daily diagnostic routine, as the corresponding equipment for proteotyping is available in modern clinical laboratories anyway. The rapidly growing sequence databases due to next generation sequencing (NGS) are opening up a wide range of opportunities for the development of further proteotyping schemes that possibly allow a rapid detection in the case of a disease outbreak.
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![Illustration of the different proteotyping steps. 1) Recording of the ICMS mass spectra of the *C. fetus* test cohort and reference strain *Cff* LMG 6442 (NCTC 10842). 2) Establishment of a *C. fetus-specific* allelic isoform list by blasting the genome sequences obtained from the NCBI database against the genome of the *C. fetus* reference strain. Subsequently, allelic isoforms in the test cohort are identified by comparing with the newly established allelic isoform list. 3) For each strain in the test cohort, a specific set of biomarker isoforms is obtained. Subsequently the amino acid sequences of the biomarkers are fused into a single sequence that results in specific proteotyping-based sequence type for each of the strains and allows the calculation of an proteotyping-derived taxonomic dendrogram](eujmi-09-062-g001){#fig001}

![ICMS spectrum of *C. fetus* subsp. *fetus* reference strain LMG 6442 (NCTC 10842). Singularly charged biomarkers that were part of the *C. fetus* proteotyping scheme labeled with a black arrow or, in the case of an *N*-terminal methionine cleavage (posttranslational modification) with a red arrow. Multiple charged ions are not marked in this illustration](eujmi-09-062-g002){#fig002}

![Overview of *C. fetus* proteotyping biomarkers (a--i). To illustrate the observed mass differences of the allelic isoforms, spectra of different proteotyping-based sequence types were overlaid using the FlexAnalysis evaluation tool. *X*-Axis: mass \[Da\]--charge ratio, scale 200 Da. *Y*-Axis: intensity \[10*x* arbitrary units\]. For the graphical illustration, the peak intensity of high but respectively lower peaks was adjusted. Color code of the spectra: Spectra of strains with the isoform of *C. fetus* subsp. *fetus* reference strain LMG 6442 (NCTC 10842) are blue, whereas the differing isoforms are colored red, green, and yellow. If the *N*-terminal methionine of a ribosomal protein was cleaved, the respective illustration is provided with an "-M"](eujmi-09-062-g003){#fig003}

![Comparison of MLST- and proteotyping-derived phylogenies. On the left: Evolutionary tree calculated based on MLST by means of the maximum composite likelihood method (UPGMA). In total, 14 different MLST sequence types were identified which are illustrated in different colors. On the right: Evolutionary tree based on proteotyping and calculated using UPGMA. Four different proteotyping-derived types were identified. Type A contains most of the *C. fetus* subsp. *fetus* and *C. fetus* subsp. *venerealis* strains. Type B and C contain 2 MLST ST 5 and one MLST ST 20 strain. The most interesting proteotyping-derived type is type D, which contains all *C. fetus* subsp. *testudinum* strains and thereby allows the differentiation of the subspecies from other *C. fetus* subspecies. The different proteotyping-based sequence types are marked at the branches of the evolutionary tree (A, B, C, and D).](eujmi-09-062-g004){#fig004}

###### 

List of *C. fetus* isolates used in the study

  -----------------------------------------------------------------------------------------------------------------------------
  Isolate         Origin                    Region                      Date         Other strain designations        MLST-ST
  --------------- ------------------------- --------------------------- ------------ -------------------------------- ---------
  *Cfv*0018       Preputial washing         Lower-Saxony                28.04.2009                                    4

  *Cfv*145/05     Preputial washing         S-Bavaria                   02.08.2005                                    4

  *Cfv*0114       Vaginal sample cattle     Lower-Saxony                19.12.2006                                    4

  *Cfv*151/05     Preputial washing         S-Bavaria                   10.08.2005                                    4

  *Cfv*93/05      Preputial washing         Thuringia                   10.05.2005                                    6

  *Cff*94/05      Preputial washing         Thuringia                   12.05.2005                                    6

  *Cfvi* 96/05    Preputial washing         Thuringia                   12.05.2005                                    4

  *Cff*225/04     Fetus calf                Thuringia                   16.12.2004                                    3

  *Cff*512/99     Calf intestinal content   Thuringia                   24.09.1999                                    5

  *Cfv*63/05      Preputial washing         N-Bavaria                   6.03.2005                                     4

  *Cfv*11/05      Preputial washing         N-Bavaria                   21.01.2005                                    4

  *Cfv*BS122/05   Fetus, cattle             Baden-W.                    14.06.2005                                    4

  *Cfv*07BS0007   Preputial washing         Baden-W.                    26.09.2007                                    4

  *Cfv*134/65     Fetus cattle              S-Bavaria                   12.07.2005                                    4

  *Cff*201/05     \-                        Thuringia                   23.11.2005                                    2

  *Cff*91/05      Preputial washing         Thuringia                   12.05.2005                                    6

  *Cff*155/60s    Preputial washing         Baden-W.                    07.09.2006                                    6

  *Cff*222/04     Bovine sperm              Saxony                      16.12.2004                                    2

  *Cff*45361      Human blood culture       Germany                                                                   3

  *Cff*169361     Human blood culture       Germany                                                                   3

  *Cff*148/5361   Human blood culture       Germany                                                                   3

  *Cfv*LMG6443    Cow, vaginal mucus        United Kingdom              1962         ATCC 19438; CCUG 538;\           4
                                                                                     CIP 68.29; JCM 2528;\            
                                                                                     NCDO 1876; NCTC 10354;\          
                                                                                     Park X/161/5                     

  *Cff*LMG6442    Sheep fetus brain         Sweden, Göteborg            1972         ATCC 27374; CCTM La3023;\        3
                                                                                     CCUG 6823A; CECT 564;\           
                                                                                     CIP 53.96; JCM 2527;\            
                                                                                     LMG 8849; NCTC 10842;\           
                                                                                     NIAH 1049;\                      
                                                                                     Vinzent strain Mouton 1          

  *Cfv*LMG6570    Cattle                    Belgium                     1985         CCUG 7477; CIP 53.105;\          4
                                                                                     Florent 483; NIDO 483            

  *Cff*71721      Human blood culture       Germany, Duderstadt         2016                                          3

  *Cff*82014      Human blood culture       Germany, Herzberg am Harz   2015                                          68

  *Cft*LMG27499   Human blood culture       USA New York                2003         ATCC BAA-2539; Blaser 03--427    15

  *Cff*LMG06569   Calf fetus                Belgium                     1985         CCUG 17693; CIP 68.8;\           11
                                                                                     Florent 7572; NIDO 7572          

  *Cff*LMG06571   Bull genitals             Belgium                     1985         CCUG 17694; De Keyser 2125/4;\   3
                                                                                     NIDO 2125/4                      

  *Cff*LMG06727                             Belgium                     1985         CCUG 17695A; LMG 6628 t1         2
  -----------------------------------------------------------------------------------------------------------------------------

###### 

Theoretical biomarker masses predicted by the genome sequence of *C. fetus* reference strain LMG 6442 (NCTC 10842) under consideration of possible posttranslational modifications

  Biomarker   \[-Met M + H^+^\]   \[-Met mM + H^+^\]   \[-Met + PO4 M + H^+^\]   \[M + H^+^\]   \[fM + H^+^\]
  ----------- ------------------- -------------------- ------------------------- -------------- ---------------
  L36         4197                4211                 4277                      **4332**       4360
  L34         5083                5097                 5163                      **5218**       5246
  L32-M       **5527**            5541                 5607                      5662           5690
  L33-M       **6202**            6216                 6282                      6337           6365
  S14-M       **6725**            6739                 6805                      6860           6888
  L29         6759                6773                 6839                      **6894**       6922
  L24-M       **8023**            8037                 8103                      8158           8186
  S20-M       **9738**            9752                 9818                      9873           9901
  S19-M       **10,274**          10,288               10,354                    10,409         10,437

\[-Met mM + H^+\]^ = methylated mass - demethioninated form.

\[-Met +PO4 M + H^+^\] = phosphorylated mass - demethioninated form.

\[M + H^+^\] = unmodified mass.

\[fM + H^+^\] = formylated mass.

###### 

Primers used for sequencing of *C. fetus* genes coding for ribosomal proteins included in the proteotyping scheme

  Biomarker   Gene   Forward primer \[5′→3′\]   Reverse primer \[5′→3′\]   Amplicon length \[bp\]
  ----------- ------ -------------------------- -------------------------- ------------------------
  L36         RpmJ   CGGGTGATCGCGTTAAAGTT       TACGAATCGCAGCAGCTTCA       522
  L34         RpmH   AGTTATGCCGCAAACACCTAT      TTTTCAAGCCCTGCTTTTGCT      699
  L32-M       RpmF   ACCACTATTGTGATAGATGCGGT    ACATCAGTAGCACTTTCTCCCA     596
  L33-M       RpmG   CCCAGTTGCACTTGAAGAAGG      ACGATCGCTACAACAGCAAAT      539
  S14-M       RpsN   AGGACTTCCGTGGTCTTCCA       ACGCTTCTACCACGTTCGTC       624
  L29         RpmC   CGCCAGATAGAATCAGCTCGT      GCGGAAGCTTTTTCTAGCAC       701
  L24-M       RpIX   TTTGACGAAAATGCAGCCGT       ACTGGGAAGCCTTCACGAAC       621
  S20-M       RpsT   TTCTCCGGCTCTGCCTCTAA       GCGAGTTCGCCTAGTTCTGG       736
  S19         RpsS   GGGCAAACGTAACTATCGGC       GAACAGGACCGGCATCTACT       752

###### 

*C. fetus*-specific allelic isoform list

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Locus                                         Full name/product\                                                                                       Calc. average mass\   Frequency in database   
                                                (ORF Locus tag in LMG 6442)                                                                              \[Da\]                                        
  --------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------- ----------------------- ------------------
  RpmJ/L36                                                                                                                                                                                             

  Sequence                                      MKVRPSVKKMCDKCKIVKRKGIVHVICENPKHKQRQG (37aa)                                                                                                           

  1^*[a](#table4-tfn1){ref-type="table-fn"}*^   reference isoform LMG 6442 (NCTC 10842)                                                                  4331.35               ±0.00                   100.000% (67/67)

  RpmH/L34                                                                                                                                                                                             

  Sequence                                      MKRTYQPHKTPKKRTHGFRGRMKTKNGRKVINARRAKGRKRLAA (44aa)                                                                                                    

  1^*[a](#table4-tfn1){ref-type="table-fn"}*^   reference isoform LMG 6442 (NCTC 10842)                                                                  5217.26               ±0.00                   47.761% (32/67)

  2^*[a](#table4-tfn1){ref-type="table-fn"}*^   MKRTYQPHKTPKKRTHGFRERMKTKNGRKVINARRAKGRKRLAA(44aa)                                                       5289.32               +72.06                  32.836% (22/67)

  3                                             MKRTYQPHKTPKKRTHGFRERMRTKNGRKVLNARRAKGRKRLAA(44aa)                                                       5317.33               +100.07                 19.403% (13/67)

  RpmF/L32-M\]                                                                                                                                                                                         

  Sequence                                      (M)AVPKRRVSHTRAAKRRTHYKVTLPMPVKDKDGSWKMPHRINKTTGEY^*[a](#table4-tfn1){ref-type="table-fn"}*^ (48aa)                                                    

  1^*[a](#table4-tfn1){ref-type="table-fn"}*^   reference isoform LMG 6442 (NCTC 10842)                                                                  5530.47               ±0.00                   77.941% (53/68)

  2                                             (M)AVPKRRVSHTRAAKRRTHYKVTLPMPVKDKDGSWKMPHRMNKTTGEY (48aa)                                                5548.50               +18.03                  17.647% (12/68)

  3                                             (M)AVPKRRVSHTRAAKRRTHYKVTLPMPVKDKDGSWKMPHRINKITGEY (48aa)                                                5542.52               +12.05                  1.471% (1/68)

  4                                             (M)AVPKRRVSHTRAAKCRTHYKVTLPMPVKDKDGSWKMPHRINKTTGEY (48aa)                                                5477.42               --53.05                 1.471% (1/68)

  5                                             (M)AVPKRLVSHTRAAKRRTHYKVTLPMPVKNKDGSWKMPHRINKTTGEY (48aa)                                                5486.45               --44.02                 1.471% (1/68)

  6^*[a](#table4-tfn1){ref-type="table-fn"}*^   (M)AVPKRRVSHTRAAKRRTHYKITLPMPVKDKDGSWKMPHRINKTTGEY (48aa)                                                5544.49               +14.02                  New sequence

  RpmG/L33-M                                                                                                                                                                                           

  Sequence                                      (M)ASANRVKIGLKCAECNDINYTTTKNSKTTTEKLELKYCPRLKKHTVHKEVKLK (55aa)                                                                                        

  1^*[a](#table4-tfn1){ref-type="table-fn"}*^   reference isoform LMG 6442 (NCTC 10842)                                                                  6205.31               ±0.00                   46.970% (31/66)

  2                                             (M)ASANRIKIGLKCVECGDINYTTTKNSKKTTEKLELKKYCPRLKKHTEHKEVKLK (55aa)                                         6247.39               +42.08                  18.182% (12/66)

  3^*[a](#table4-tfn1){ref-type="table-fn"}*^   (M)ASANRVKIGLKCAECNDINYTTTKNSKKTTEKLELKKYCPRLKKHTVHKEVKLK (55aa)                                         6232.38               +27.07                  33.333% (22/66)

  4                                             (M)ASVNRIKIGLKCVECGDINYTTTKNSKKTTEKLELKKYCPRLKKHTEHKEVKLK (55aa)                                         6275.44               +70.13                  1.515% (1/66)

  5^*[a](#table4-tfn1){ref-type="table-fn"}*^   (M)ASANRVKIGLKCAECNDINYTTTKNSKTTTEKSELKKYCPRLKKHTVHKEVKLK (55aa)                                         6179.23               --26.08                 New sequence

  RpsN/S14-M                                                                                                                                                                                           

  Sequence                                      (M)AKKSMIAKAARKPKFSARGYTRCQICGRPHSVYKFGICRVCLRKMANEGLIPGLKKASW (61aa)                                                                                  

  1^*[a](#table4-tfn1){ref-type="table-fn"}*^   reference isoform LMG 6442 (NCTC 10842)                                                                  6728.11               ±0.00                   80.303% (53/66)

  2                                             (M)AKKSMIAKAARKPKFSVRGYTRCQICGRPHSVYKDFGICRVCLRKMANEGLIPGLKKASW (61aa)                                   6756.16               +28.05                  3.030% (2/66)

  3                                             (M)AKKSMIAKAARAPKFSSRGYTRCQICGRPHSVYKDFGICRVCLRKMANEGLIPGLKKASW (61aa)                                   6687.01               +41.10                  16.667% (11/66)

  RpmC/L29                                                                                                                                                                                             

  Sequence                                      MKYIDISAKSMSELNALLKEKKVLLFTLRQKLKTMQLTNPNEIGETKKDIARINTAISAAK (61aa)                                                                                   

  1^*[a](#table4-tfn1){ref-type="table-fn"}*^   reference isoform LMG 6442 (NCTC 10842)                                                                  6893.22               ±0.00                   47.761% (32/67)

  2                                             MKYTEISAKSVSELTALLKEKKVLLFTLRQKLKTMQLTNPNEIRDTKKEIARINTAI SAAK (61aa)                                    6949.27               +56.05                  19.403% (13/67)

  3^*[a](#table4-tfn1){ref-type="table-fn"}*^   MKYIDISAKSISELNALLKEKKVLLFTLRQKLKTMQLTNPNEIRDTKKEIARINTAISAAK(61aa)                                      6974.32               +81.10                  32.836% (22/67)

  RplX/L24-M                                                                                                                                                                                           

  Sequence                                      (M)AVKYKIKKGDEVKVIAGDDKGKVAKVIAVLPKKGQVIVEGVKVAKKAVKPTEKNPNGGFISKEMPIDISNVAKVEG (77aa)                                                                 

  1^*[a](#table4-tfn1){ref-type="table-fn"}*^   reference isoform LMG 6442 (NCTC 10842)                                                                  8026.59               ±0.00                   47.751% (32/67)

  2                                             (M)AIKYKIKKGDEVKVIAGDDKGKVAKVLAVLPKKGQVIVEGVKVAKKAVKPTDKNPNGGFVSKEMPIDISNVAKVEG (77aa)                   8012.56               --14.03                 17.910% (12/67)

  3^*[a](#table4-tfn1){ref-type="table-fn"}*^   (M)AVKYKIKKGDEVKVIAGDDKGKVAKVIAVLPKKGQVIVEGVKVAKKAVKPTDKNPNGGFISKEMPIDISNVAKVEG (77aa)                   8012.56               --14.03                 32.836% (22/67)

  4                                             (M)AIKYKIKKGDEVKVIAGDDKGKVAKVLAVLPKKGQVIVEGIKVAKKAVKPTDKNPNGGFVSKEMPIDISNVSKVEG (77aa)                   8042.59               +16.00                  1.493% (1/67)

  RpsT/S20-M                                                                                                                                                                                           

  Sequence                                      (M)ANHKSAEKRARQTIKRTERNRFYRTRLKNLTKAVRVAVASGDKDAALVALKDANKNFHSFVSKGFLKKETASRKVSRLAKLVSTLAA (88aa)                                                      

  1^*[a](#table4-tfn1){ref-type="table-fn"}*^   reference isoform LMG 6442 (NCTC 10842)                                                                  9741.33               ±0.00                   48.529% (33/68)

  2                                             (M)ANHKSAEKRARQTIKRTERNRFYRTRLKNLTKAVRVAVANGDKDAALLALKDVNKNFHSFVSKGFLKKETASRKVSRLAKLVSTLAA (88aa)        9810.43               +69.10                  16.176% (11/68)

  3                                             (M)ANHKSAEKRARQTIKRTERNRFYRTRLKNLTKAVRVAVANGDKDAALLALKDVNKNFHSFVSKGFLKKKTASRKVSRLAKLVSTLAA (88aa)        9809.49               +68.14                  1.471% (1/68)

  4^*[a](#table4-tfn1){ref-type="table-fn"}*^   (M)ANHKSAEKRARQTIKRTERNRFYRTRLKNLTKAVRVAVTSGDKDAALLALKDVNKNFHSFVSKGFLKKETASRKVSRLAKLVSTLAA (88aa)        9813.43               +72.10                  32.353% (22/68)

  5                                             (M)ANHKSAEKRARQTIKRTERNRFYRTRLKNLTKAVRVAVANGDKDAALLALKDVNKNFHSFVSKGFLKKETASRKVGRLAKLVSTLAA (88aa)        9780.41               +39.08                  1.471% (1/68)

  RpsS/S19-M                                                                                                                                                                                           

  Sequence                                      (M)ARSLKKGPFVDDHVMKKVLAAKAANDNKPIKTWSRSMIIPEMIGLFNVHNGKGFIPVYVTENHIGYKLGEFAPTRTFKGHKGSQKKIGK (93aa)                                                    

  1^*[a](#table4-tfn1){ref-type="table-fn"}*^   reference isoform LMG 6442 (NCTC 10842)                                                                  10277.10              ±0.00                   47.761% (32/67)

  2                                             (M)ARSLKKGPFVDDHVMKKVLAAKAANDNKPIKTWSRRSTIIPEMIGLTFNVHNGKSFIPVYVTENHIGYKLGEFAPTRTFKGHKGSVQKKIGK (93aa)   10277.04              --0.06                  14.925% (10/67)

  3^*[a](#table4-tfn1){ref-type="table-fn"}*^   (M)ARSLKKGPFVDDHVMKKVLAAKAANDNKPIKTWSRRSMIIPEMIGLTFNVHNGKSFIPVYVTENHIGYKLGEFAPTRTFKGHKGSVQKKIGK (93aa)   10307.12              +30.02                  32.836% (22/67)

  4                                             (M)ARSLKKGPFVDDHVMEKVLAAKATNDNKPIKTWSRRSTIIPEMIGLTFNVHNGKSFIPVYVTENHIGYKLGEFAPTRTFKGHKGSVQKKIGK (93aa)   10308.00              +30.90                  4.478% (3/67)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*a*^Observed in test population AA numbering including start-methionine, if mass spectrometry indicates its absence it is written in brackets (M).

###### 

Accession numbers of *C. fetus*-specific proteotyping biomarker isoforms

  Biomarker   Isoform   Gene Bank Accession              Locus Tag      Protein ID
  ----------- --------- -------------------------------- -------------- ------------
  L36         1         MK463617                                        
  L34         1         CP000487.1:557520--557,654       CFF8240_0551   ABK82017.1
  L34         2         CP027287.1:608973--609,107       C6B32_03095    AVK80859.1
  L32-M       1         CP000487.1:210702--210,848       CFF8240_0235   ABK81894.1
  L32-M       6         MK463615                                        
  L33-M       1         CP000487.1:1313847--1,313,949    CFF8240_1324   ABK82614.1
  L33-M       3         CP027287.1:c1398913--1,398,746   C6B32_06940    AVK81560.1
  L33-M       5         MK463616                                        
  S14-M       1         CP000487.1:39526--39,711         CFF8240_0047   ABK82398.1
  L29         1         CP000487.1:37925--38,110         CFF8240_0042   ABK82084.1
  L29         3         CP027287.1:36898--37,083         C6B32_00200    AVK80319.1
  L24-M       1         CP000487.1:38746--38,979         CFF8240_0045   ABK83333.1
  L24-M       3         CP027287.1:37719--37,952         C6B32_00215    AVK80322.1
  S20-M       1         CP000487.1:1678191--1,678,457    CFF8240_1718   ABK82453.1
  S20-M       4         CP027287.1:1762618--1,762,884    C6B32_08820    AVK81906.1
  S19-M       1         CP000487.1:36187--36,468         CFF8240_0038   ABK81869.1
  S19-M       3         CP027287.1:35160--35,441         C6B32_00180    AVK80315.1

###### 

Measured and calculated biomarker masses

  Biomarker   Isoform     Measured mass (Da)   Standard deviation   Δ Measured mass/average mass   Monoisotopic mass (Da)   Average mass (Da)
  ----------- ----------- -------------------- -------------------- ------------------------------ ------------------------ -------------------
  L36         Isoform 1   4331                 0.765                0.35                           4328.40                  4331.35
  L34         Isoform 1   5217                 0.425                0.26                           5214.02                  5217.26
  L34         Isoform 2   5290                 0.593                0.68                           5286.04                  5289.32
  L32-M       Isoform 1   5530                 0.478                0.47                           5526.99                  5530.47
  L32-M       Isoform 6   5544                 0.475                0.49                           5541.01                  5544.49
  L33-M       Isoform 1   6205                 0.867                0.31                           6201.37                  6205.31
  L33-M       Isoform 3   6232                 0.381                0.38                           6228.42                  6232.38
  L33-M       Isoform 5   6179                 0.271                0.23                           6175.32                  6179.23
  S14-M       Isoform 1   6728                 0.445                0.11                           6854.63                  6728.11
  L29         Isoform 1   6893                 0.321                0.22                           6888.84                  6893.22
  L29         Isoform 3   6975                 0.877                0.68                           6969.96                  6974.32
  L24-M       Isoform 1   8026                 0.928                0.59                           8021.62                  8026.59
  L24-M       Isoform 3   8012                 0.620                0.56                           8007.61                  8012.56
  S20-M       Isoform 1   9741                 0.959                0.33                           9735.50                  9741.33
  S20-M       Isoform 4   9813                 0.361                0.43                           9807.56                  9813.43
  S19-M       Isoform 1   10,277               0.499                0.10                           10270.58                 10277.10
  S19-M       Isoform 3   10,308               0.635                0.88                           10300.59                 10307.12
